Telos Corporation
NASDAQ:TLSInformation Technology Services
-$0.01 today
- Market cap
- $544.88M
- Beta
- 0.97
- P/E (TTM)
- -12.4
- EPS (TTM)
- -$0.35
Volume 0.84M
Average 0.87M
TLS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Telos CorporationNASDAQ: TLS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $3.43M rose 46.8% year over year, ahead of the +13.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +24.8% a year.
Context
- Depreciation & amortization amounted to 6.9% of revenue in FY2025, down 4.0 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +46.8% holds above the trailing-twelve-month pace of +13.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 11.45M USD
- Year-over-year change
- -3.5%
- 4-year CAGR
- +19.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.45M | -3.5% |
| FY2024 | 2024-12-31 | 11.87M | +25.9% |
| FY2023 | 2023-12-31 | 9.43M | +60.1% |
| FY2022 | 2022-12-31 | 5.89M | +4.7% |
| FY2021 | 2021-12-31 | 5.62M | — |
Depreciation & Amortization vs competitors
How TLS compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +13.3% is the 6th highest of 9, against a peer median of +27.8%.
- Depreciation & amortization amounts to 6.9% of revenue for TLS, versus a peer median of 4.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $371M USD | +34.9% | +7.0% | 5.0% | |
| LTM Mar 2026 | $278.05M USD | +1.2% | +1.2% | 16.0% | |
| LTM Mar 2026 | $59.56M USD | +20.7% | +17.1% | 7.6% | |
| LTM Mar 2026 | $18.55M USD | +5.4% | -1.6% | 3.0% | |
| LTM Mar 2026 | $12.54M USD | +13.3% | +24.8% | 6.9% | |
| LTM Mar 2026 | $12.34M USD | +46.7% | +12.5% | 5.0% | |
| LTM Mar 2026 | $9.73M USD | -11.8% | -23.9% | 3.2% | |
| LTM Mar 2026 | $5.7M USD | +36.2% | +6.8% | 1.9% | |
| LTM Mar 2026 | $4.8M USD | +543.0% | +114.2% | 2.4% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥1.54M CNY | — | -76.2% | — |
| Peer median (excluding TLS) | — | +27.8% | +6.8% | 4.1% | |
Competitors are the stored peer set for TLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.13M) | (53.43M) | (34.42M) | (52.52M) | (36.55M) |
| Depreciation & Amortization | 5.62M | 5.89M | 9.43M | 11.87M | 11.45M |
| Deferred Income Tax | 70K | 35K | 55K | 0 | (760K) |
| Stock-Based Compensation | 60.23M | 64.66M | 24.4M | 21.41M | 30.15M |
| Change in Working Capital | (15.57M) | (800K) | 3.33M | (18.55M) | 11.22M |
| Accounts Receivables | (28.94M) | 19.68M | 9.49M | 11.27M | 2.17M |
| Inventory | 2.05M | (1.63M) | 1.46M | (471K) | 634K |
| Accounts Payables | 16.09M | (12.32M) | (8.82M) | (9.42M) | 2.72M |
| Other Working Capital | (4.77M) | (6.52M) | 1.2M | (19.94M) | 5.69M |
| Other Non-Cash Items | 42K | 151K | (1.2M) | 11.86M | 14.67M |
| Operating Cash Flow | 7.26M | 16.51M | 1.59M | (25.94M) | 30.18M |
| Capital Expenditures | (13.17M) | (13.72M) | (15.48M) | (2.25M) | (739K) |
| Acquisitions (Net) | (5.93M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (3M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (9.97M) | (12.71M) | (14.55M) | (11.51M) | (8.18M) |
| Investing Cash Flow | (19.09M) | (13.72M) | (15.48M) | (16.76M) | (8.92M) |
| Debt Repayment | (1.34M) | (1.46M) | (1.59M) | (1.73M) | (1.88M) |
| Common Stock Issued | 64.27M | 0 | 0 | 203K | 108K |
| Common Stock Repurchased | (1.25M) | (11.15M) | (139K) | 0 | (13.63M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (29.33M) | 2.69M | (4.42M) | (457K) | (7.27M) |
| Financing Cash Flow | 32.35M | (9.92M) | (6.15M) | (1.98M) | (22.66M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 20.52M | (7.12M) | (20.04M) | (44.68M) | (1.4M) |
| Free Cash Flow | (5.91M) | 2.79M | (13.89M) | (28.19M) | 29.44M |
Telos Corporation
NASDAQ:TLS
Intrinsic Alpha fair value
Locked
Current Price
$7.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.